REHOVOT, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 5,633,509 American Depositary Shares (ADSs), each representing 10 ordinary shares, having original exercise prices ranging ...

New data suggests that baseline serum myeloperoxidase (MPO) levels below the threshold may predict overall survival (OS) improvement when comparing the CM24+nivolumab+Nal-IRI/5FU/LV vs. NalIRI/5FU/LV arms Data reported at the 2024 ASCO annual meeting demonstrated reduced risk of death and cancer progression, prolongation of OS and progression free survival (PFS) as well as higher objective response rate (ORR) and disease control rate (DCR) and decreasing CA19-9 levels in the CM24+Nivolumab+NalIRI/5FU/LV arm ...

New data suggests that baseline serum myeloperoxidase (MPO) levels below the threshold may predict overall survival (OS) improvement when comparing the CM24+nivolumab+Nal-IRI/5FU/LV vs. NalIRI/5FU/LV arms Data reported at the 2024 ASCO annual meeting demonstrated reduced risk of death and cancer progression, prolongation of OS and progression free survival (PFS) as well as higher objective response rate (ORR) and disease control rate (DCR) and decreasing CA19-9 levels in the CM24+Nivolumab+NalIRI/5FU/LV arm ...

Michael Cecchini, MD Assistant Professor of Medicine at the Yale Cancer Center, a principal investigator in this study, commented, "As a clinician, it is encouraging to see these interim data in the Nal-IRI arm suggesting the potential for improved clinical outcomes for patients with late-stage metastatic PDAC who are in dire need of new effective therapies. These patients face very limited time with their families, and the prospect of potentially lengthening their lives while delaying their disease progres ...

REHOVOT, Israel, May 21, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the three months ended March 31, 2024. "We look forward to presenting compelling interim Phase 2 CM24 data for the treatment of pancreatic cancer at ASCO 2024, where we were selec ...

Core Insights - Purple Biotech Ltd. reported financial results for Q1 2024, highlighting progress in clinical trials and a focus on developing therapies targeting tumor immune evasion and drug resistance [1][21]. Financial Performance - Research and Development Expenses were $3.4 million for Q1 2024, a decrease of 2.8% from $3.5 million in Q1 2023 [13]. - Sales, General and Administrative Expenses were $1 million for Q1 2024, down from $1.6 million in Q1 2023, representing a decrease of $0.6 million [13]. - Operating Loss for Q1 2024 was $4.5 million, a reduction of 11.8% compared to $5.1 million in Q1 2023 [14]. - Net Loss for Q1 2024 was $3.8 million, or $0.14 per basic and diluted ADS, compared to a net loss of $4.9 million, or $0.25 per basic and diluted ADS in Q1 2023 [15]. - As of March 31, 2024, the company had cash and cash equivalents of $10.8 million, providing a cash runway into Q1 2025 [16]. Clinical Developments - The company is set to present interim Phase 2 data for CM24 in pancreatic cancer at ASCO 2024, which may indicate reduced risk of disease progression and death [2][4]. - NT219 is progressing towards a Phase 2 trial in head and neck cancer, with positive early results presented at ESMO-TAT 2024 showing a 29% objective response rate and a 71% disease control rate [6][9]. - The tri-specific antibody platform is expected to produce promising drug candidates, with the lead asset IM1240 anticipated to be ready for Phase 1 study by early 2026 [19]. Research Highlights - The Phase 2 study of CM24 is evaluating its efficacy in combination with nivolumab and standard chemotherapy in advanced pancreatic cancer patients [5]. - NT219 has shown potential in suppressing cancer stem cells and overcoming resistance to KRAS inhibitors, with findings presented at AACR 2024 [7][9]. - A Scientific Advisory Board has been established to guide the development of NT219 in combination with cetuximab for recurrent/metastatic head and neck cancer [11].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of e ...

Financial Performance - Net Loss for 2023 was $20 million, or $0.90 per basic and diluted share, compared to a net loss of $21.8 million, or $1.20 per share, in 2022[18] - Adjusted net loss for 2023 was $22.1 million, an increase from $19.6 million in 2022[18] - Operating loss for the year was USD 22,271 thousand in 2023, slightly down from USD 22,603 thousand in 2022, a decrease of approximately 1.5%[30] - Net loss for the year decreased to USD 19,977 thousand in 2023 from USD 21,760 thousand in 2022, a reduction of about 8.2%[30] - The total comprehensive loss for the period was USD 19,952 thousand in 2023, compared to USD 21,766 thousand in 2022, a decrease of approximately 8.3%[30] - The company reported a basic and diluted loss per ADS of USD 0.90 for the year ended December 31, 2023, compared to USD 1.20 in 2022, a decrease of 25%[30] Expenses - Research and Development Expenses for 2023 were $17 million, an increase of $0.7 million, or 4.3%, compared to $16.3 million in 2022[14] - Selling, General and Administrative Expenses decreased to $5.2 million in 2023 from $6.3 million in 2022, a reduction of $1.1 million[15] - Research and development expenses increased to USD 17,034 thousand in 2023 from USD 16,320 thousand in 2022, representing a growth of about 4.4%[30] Cash and Assets - As of December 31, 2023, cash and cash equivalents were $15.3 million, down from $31.7 million on December 31, 2022, providing a cash runway into the first half of 2025[19] - Cash and cash equivalents at the end of the period were USD 14,489 thousand, down from USD 15,030 thousand at the beginning of the period, a decrease of approximately 3.6%[31] - Total assets decreased from USD 54,622 thousand in 2022 to USD 44,302 thousand in 2023, a decline of approximately 19%[29] - Total equity attributable to owners of the company decreased from USD 46,911 thousand in 2022 to USD 34,207 thousand in 2023, a decline of approximately 27.3%[29] - Total current liabilities remained relatively stable, increasing slightly from USD 7,058 thousand in 2022 to USD 7,183 thousand in 2023, an increase of about 1.8%[29] Research and Development Progress - The Phase 2 study for CM24 completed enrollment of approximately 60 patients ahead of schedule in December 2023, with interim data expected in H1 2024[5] - NT219 demonstrated a tumor objective response rate (ORR) of 29% and a disease control rate (DCR) of 71% in a Phase 1 study, with a recommended Phase 2 dose of 100 mg/kg[10] - The company plans to commence a Phase 2 study of NT219 in H1 2024, following positive results from the Phase 1 study[11] - The lead tribody in development, IM1240, is expected to be ready for an Investigational New Drug (IND) filing in approximately two years[13] Finance Income - Finance income for 2023 was $2.3 million, an increase of $1.5 million, or 188%, compared to $0.8 million in 2022[17] - The company raised USD 5,000 thousand from the issuance of ADSs, warrants, and prefunded warrants during the year[31]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of e ...

Exhibit 99.1 Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results Expands pipeline with acquisition of new tri-specific antibodies Data readouts for two lead clinical programs expected in 2023 REHOVOT, Israel, February 8, 2023 – (GLOBE NEWSWIRE) Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment to overcome tumor immune evasi ...